Radcliffe CVRM

@RadcliffeCVRM

Advancing the understanding and treatment of cardiovascular, renal and metabolic risk.

Joined February 2025

116Following

34Followers

Radcliffe CVRM@RadcliffeCVRM · Jul 24

👣Advancing #PAD care with #GLP1 therapies 📽️Drs @MarcBonaca & @hvanspall discuss how #semaglutide improved walking ability and QoL in pts with #T2D & PAD 👉 ow.ly/eHCx50WuLUl 📽️Dr @Catgobears on GLP1 RAs reducing amputation risk in moderate PAD 👉 ow.ly/XerM50WuLUm

522

Radcliffe CVRM@RadcliffeCVRM · Jul 22

💡This key review in #CFRJournal explores the haemodynamic effects of #SGLT2i therapy in chronic #HF 🔓📖Access now 👉 ow.ly/5Gk350Wtsbx #HFpEF #HFrEF #CVRM #CardioEd #Finerenone #Dapagliflozin #Empagliflozin

RadcliffeCVRM's tweet image. 💡This key review in #CFRJournal explores the haemodynamic effects of #SGLT2i therapy in chronic #HF

🔓📖Access now 👉 ow.ly/5Gk350Wtsbx

#HFpEF #HFrEF #CVRM #CardioEd #Finerenone #Dapagliflozin #Empagliflozin

Radcliffe CVRM@RadcliffeCVRM · Jul 19

📚 Latest News : "Total ApoB and Lp(a) Count Deemed Superior for CAD Risk Assessment" 📚 For assessing lipid-related cardiovascular risk, a new study suggests it's the total count of apoB and Lp(a) particles that matters most, not their size or type. 👉 ow.ly/ULai106ggGl

RadcliffeCVRM's tweet image. 📚 Latest News : "Total ApoB and Lp(a) Count Deemed Superior for CAD Risk Assessment"

📚 For assessing lipid-related cardiovascular risk, a new study suggests it's the total count of apoB and Lp(a) particles that matters most, not their size or type.

👉 ow.ly/ULai106ggGl

Radcliffe CVRM@RadcliffeCVRM · Jul 18

💡Dr @MKIttlesonMD discusses key updates and recommendations from the 2025 ACC Scientific Statement on the Management of #Obesity in Adults with #HeartFailure. 📽️Watch here👉 ow.ly/bU2950WrRuO 💭What are the new recommendations? #HF #CVRM #CardioEd

Radcliffe CVRM@RadcliffeCVRM · Jul 18

📚 Latest News : "Increased Systolic Blood Pressure Variability Over Time Linked to Higher Risk of CVD, CKD, and Death" 🔓Access it here 👉 ow.ly/wnZ1106g9Fk

RadcliffeCVRM's tweet image. 📚 Latest News : "Increased Systolic Blood Pressure Variability Over Time Linked to Higher Risk of CVD, CKD, and Death"

🔓Access it here 👉 ow.ly/wnZ1106g9Fk

Radcliffe CVRM@RadcliffeCVRM · Jul 17

🔍Key insights on #tirzepatide from the SURPASS trials Dr Ellen Apperloo highlights the kidney benefits of tirzepatide in pts with #T2D, including significant reductions in uACR vs comparators like #semaglutide and insulin. 📽️👉 ow.ly/gQqV50Wrlts #CVRM #CKM #CardioEd

Radcliffe CVRM@RadcliffeCVRM · Jul 17

📚 Latest News : "Absence of Five Key Risk Factors at 50 Adds Over a Decade of Life" 📚 Having no key cardiovascular risk factors at age 50 can add more than a decade of life, a major new global study finds. 👉 ow.ly/XTU7106g2QE

RadcliffeCVRM's tweet image. 📚 Latest News : "Absence of Five Key Risk Factors at 50 Adds Over a Decade of Life"

📚 Having no key cardiovascular risk factors at age 50 can add more than a decade of life, a major new global study finds.

👉 ow.ly/XTU7106g2QE

Radcliffe CVRM@RadcliffeCVRM · Jul 15

💡This #CFRJournal review explores the impact of GLP-1 RAs on cardiac structure, function, exercise capacity and QoL in patients with #HF across the #LVEF spectrum. 🔓📖Access now 👉 ow.ly/LTjV50WpTAN #CKM #CVRM #HFpEF #GLP1 #CardioEd

RadcliffeCVRM's tweet image. 💡This #CFRJournal review explores the impact of GLP-1 RAs on cardiac structure, function, exercise capacity and QoL in patients with #HF across the #LVEF spectrum.

🔓📖Access now 👉 ow.ly/LTjV50WpTAN

#CKM #CVRM #HFpEF #GLP1 #CardioEd

Radcliffe CVRM@RadcliffeCVRM · Jul 12

💡Dr @ArunJSanyalVCU shares insights from the phase 3 ESSENCE trial examining #semaglutide 2.4 mg for metabolic dysfunction-associated #steatohepatitis. 📽️Watch here👉 ow.ly/Z6nY50WoxQL #MASH #CKM #CVRM #CardioX #CardioEd

1.0K

Radcliffe CVRM@RadcliffeCVRM · Jul 11

🧠💊 Smarter decisions, better outcomes. How can decision support systems improve early lipid-lowering strategies after #ACS? 🔍 Dr @hvanspall & @ProfKausikRay unpack findings from the ZODIAC trial. 📽️ Watch in full here 👉 ow.ly/Xztv50WohAQ #CKM #CVRM #CardioEd

Radcliffe CVRM@RadcliffeCVRM · Jul 10

🔍Where are the gaps in #HF and #CKD research? 📄✨This key editorial explores the evidence, and limitations, of current #HeartFailure therapies across age, sex and CKD severity. 🔓📖Access now 👉 ow.ly/BCa150Wn8lZ #CKM #CVRM #SGLT2i #MRA #CardioEd

RadcliffeCVRM's tweet image. 🔍Where are the gaps in #HF and #CKD research?

📄✨This key editorial explores the evidence, and limitations, of current #HeartFailure therapies across age, sex and CKD severity.

🔓📖Access now 👉 ow.ly/BCa150Wn8lZ

#CKM #CVRM #SGLT2i #MRA #CardioEd

Radcliffe CVRM@RadcliffeCVRM · Jul 9

💡Do #MRAs deliver consistent benefits across the heart failure spectrum? Prof Pardeep Jhund discusses the findings from a study evaluating MRAs in patients with #HFrEF, #HFmrEF & #HFpEF. 📽️ Watch now 👉 ow.ly/ItwN50Wn9Cp #Finerenone #HeartFailure #CVRM #CardioEd

Radcliffe CVRM@RadcliffeCVRM · Jul 9

Prof James Burton recaps the three key takeaways from our live webinar on managing hyperkalaemia. Watch here 👉 ow.ly/El4a50WmfXQ This Independent Medical Education roundtable is supported by an unrestricted educational grant from AstraZeneca.

Radcliffe CVRM@RadcliffeCVRM · Jul 8

💡Dr Richard Rosenfeld discusses key takeaways from the American College of Lifestyle Medicine practice guidelines for treatment and remission of type 2 diabetes and prediabetes. 📽️Watch here👉 ow.ly/v6rC50WmrBQ #T2D #CVRM #CardioX #CardioEd

Radcliffe CVRM@RadcliffeCVRM · Jul 3

🎙️NEW #ADA2025 #LBCT Interview 💫 @DrSuePedersen discusses the efficacy and safety of CagriSema in REDEFINE 1 and 2. 📽️ Watch here👉 ow.ly/AiQq50Wkgzj #ADA25 CVRM #CardioEd

Radcliffe CVRM@RadcliffeCVRM · Jul 2

🚨 Live in one hour – Managing Hyperkalaemia: Getting Patients to Optimal RAASi Therapy. Register here 👉 ow.ly/uQI650Wj7BX This Independent Medical Education roundtable is supported by an unrestricted educational grant from AstraZeneca.

RadcliffeCVRM's tweet image. 🚨 Live in one hour – Managing Hyperkalaemia: Getting Patients to Optimal RAASi Therapy.

Register here 👉 ow.ly/uQI650Wj7BX

This Independent Medical Education roundtable is supported by an unrestricted educational grant from AstraZeneca.

274

Radcliffe CVRM@RadcliffeCVRM · Jul 2

🎙️NEW #ADA2025 #LBCT Interview 💫Dr @AliceYYCheng discusses the STRIDE study. 📽️Watch here👉 ow.ly/jnE150WjxnY 📊Findings show #semaglutide improves walking ability in patients with #PAD and #T2D. #ADA25 #ADASciSessions #CKM #CVRM #CardioEd

Radcliffe CVRM@RadcliffeCVRM · Jul 2

🎙️NEW #ADA2025 #LBCT Interview 💫Dr John Buse discusses final results from the CATALYST trial. 📽️Watch here👉 ow.ly/juM750Wjxaw #ADA25 #ADASciSessions #CKM #CVRM #CardioEd

Radcliffe CVRM@RadcliffeCVRM · Jul 1

🎙️NEW #ADA2025 #LBCT Interview 💫Dr Harold Bays discusses a study investigating the safety and efficacy of #MariTide treatment for #obesity in patients with or without #T2D. 📽️Watch here👉 ow.ly/CBJZ50Wj3cb #ADA25 #ADASciSessions #CKM #CVRM #CardioEd

Radcliffe CVRM@RadcliffeCVRM · Jul 1

24 Hours To Go!🚨 The Rise of CVRM Medicine: Managing Common Co-morbidities as One 🔗 ow.ly/9rWW50WiZ9r This programme is supported by an unrestricted educational grant from NOVO NORDISK A/S. This content is intended for an international audience of non-US and non-UK HCPs.

RadcliffeCVRM's tweet image. 24 Hours To Go!🚨
The Rise of CVRM Medicine: Managing Common Co-morbidities as One 🔗 ow.ly/9rWW50WiZ9r

This programme is supported by an unrestricted educational grant from NOVO NORDISK A/S. This content is intended for an international audience of non-US and non-UK HCPs.